Antioxidants · 2023 · 13 citations · 51 references
Life SciencesMolecular MedicineObstetricsHigh-risk PregnancyMaternal-fetal MedicineObstetric HemorrhageAntioxidant DefenseEndothelial DysfunctionOxidative StressPlacental PhysiologyPregnancy-induced HypertensionReactive Oxygen SpeciesHypoxia-inducible Factor SignalingOxidative Stress In PregnancyOxidative Stress InjuryPlacental Development DefectsPlacental Dysfunction In PreeclampsiaPreeclampsia PathophysiologyReactive Oxygen Species GenerationReactive Oxygen Species Injury
Preeclampsia (PE) is a pregnancy-specific syndrome affecting 5–7% of patients. There is no effective treatment available. Early abnormal placental development is associated with oxidative stress (OS) and a release of reactive oxygen species (ROS) in the placenta. This phenomenon leads to downstream signaling, Hypoxia Inducible Factor 1A (HIF1A) stabilization and transcription of the anti-angiogenic factors soluble fms-like tyrosine kinase 1 (sFLT1) and soluble endoglin (sEng), which are known to cause endothelial and trophoblast dysfunction and cardinal features of PE: hypertension, proteinuria and, in severe cases, eclampsia. We tested whether 3-(Hydroxymethyl)-1-oxy-2,2,5,5-tetramethylpyrrolidine (HMP)—a nitroxide-type antioxidant molecule—can reduce placental OS and mitigate PE symptoms in vitro. We induced OS in human trophoblast (HTR-8/SVneo) cells with hydrogen peroxide (H2O2) and assessed whether modulating cell redox function with HMP reduces cell injury, mitochondrial stress and HIF1A and sFLT1 production. Pre-treatment with HMP reduced mitochondrial-derived ROS production, restored LC3B expression and reduced HIF1A and sFLT1 expression in H2O2-exposed HTR-8/SVneo trophoblast cells. HMP improved the mitochondrial electron chain enzyme activity, indicating that a reduction in OS alleviates mitochondrial stress and also reduces anti-angiogenic responses. In reducing placental trophoblast OS, HMP presents a potential novel therapeutic approach for the treatment of PE. Future investigation is warranted regarding the in vivo use of HMP.
51
Sharon E. Maynard, Jiang-Yong Min, Jaime R. Merchan et al. · Journal of Clinical Investigation · 2003 · 4K citations · Full text
Obstetrics and Gynecology · 2013 · 3.9K citations
Medicine, Gynecology, Obstetrics +9
Circulating Angiogenic Factors and the Risk of Preeclampsia
Richard J. Levine, Cong Qian, Lucinda J. England et al. · New England Journal of Medicine · 2004 · 3.6K citations · Full text
Anaelechi J. Onuegbu, Japhet M. Olisekodiaka, John U. Udo et al. · Medical Principles and Practice · 2015 · 2K citations · Full text
Soluble endoglin contributes to the pathogenesis of preeclampsia
Shivalingappa Venkatesha, Mourad Toporsian, Chun Sing Lam et al. · Nature Medicine · 2006 · 1.8K citations